Tag archive for ‘Agenus collaboration with Incyte’
Agenus: The Collaboration with Incyte is Transformative and Creates Great Shareholder Value (AGEN, Buy, $4.99)
Incyte’s expertise in clinical development and commercialization of cancer drugs is a perfect complement to Agenus’ product development capabilities for antibodies used for checkpoint modulation. The combined companies present one of the most powerful development efforts in the highly promising field of checkpoint modulation. Agenus is the only pure play in this area, which is […]